Status:
COMPLETED
the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy
Lead Sponsor:
Cairo University
Conditions:
Abdominal Myomectomy
Eligibility:
FEMALE
25-50 years
Phase:
PHASE4
Brief Summary
To investigate the effectiveness of carbetocin on reducing intraoperative blood loss during abdominal myomectomy
Eligibility Criteria
Inclusion
- • Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging
- Age ≥ 25 years and ≤ 50 years
- Pre-operative hemoglobin \>10 g/dl
- Ability to understand and the willingness to sign a written informed consent.
- Admissible medical/surgical history
- Five or less symptomatic uterine myomas
- symptomatic stage 3 to 6 fibroids, according to FIGO staging
Exclusion
- • Post-menopausal women
- Patients with known bleeding/clotting disorders
- Patients with a history of gynecologic malignancy
- Hypertension.
- Cardiac and Pulmonary diseases.
- History of allergic reactions attributed to carbetocin
Key Trial Info
Start Date :
September 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2020
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT04083625
Start Date
September 10 2019
End Date
February 20 2020
Last Update
April 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Giza hospital
Giza, Egypt, 11231